Three hundred and seven lepromatous and borderline lepromatous patients in five participating centres (Freetown, Karachi, Bombay, Madras, Chetput) were randomized to receive one of the three fo llowing drug regimens: A, DDS 100 mg/ day; B, DDS 100 mg/day + Rifa 600 mg/day; and C, Rifa 600 mg/day + Isopro dian (PTH 175 mg, INH 175 mg, dapsone 50 mg), 2 tablets/day. An adjustment was made for patients with less than 60 kg or more than 80 kg of body-weight. Criteria for exclusion included active tuberculosis, any other wasting disease, and psychic disorders. Patients who had been on regular or irregular DDS treatment for 3 years or more were ·excluded. The main characteristics of the study population are shown in Table 1 . A complete physical examination, basic laboratory tests (BUN, GOT, GPT, Hb), skin smears and histology were done before treatment and at regular intervals during the 3 years of treatment. Prior to chemotherapy, a DDS-resistance test was performed and in case of DDS resistance the patient was treated as in Group C, but excluded fr om the study and evaluated separately. Of the 228 patients who are still in the study 10 (Group D) showed to be fu lly resistant to DDS.
Comparison of DDS with two combined chemotherapy regimens
well, and there was no difference in side-effects as judged by GOT, GPT, BUN and haematology serial examinations. This preliminary evaluation shows no difference in therapeutic response between multidrug and single-drug therapy. Evidence of relapse and/or the development of DDS resistance in the fo llow-up period will be the important criteria for fu rther recommendations. 81 
